November 2009

Drug Testing Index with Hair Testing

by Aaron Atkinson on November 20, 2009

New data released today by Quest Diagnostics Incorporated (NYSE: DGX), the nation’s leading provider of employment-related drug testing services, reveal that drug testing of hair specimens from employees and job applicants in the general U.S. workforce has tracked sharp downward trends in cocaine and methamphetamine use from 2005 to the first half of 2009 that mirror similar drops shown by urine testing. Data in the Quest Diagnostics Drug Testing Index™ (DTI) special report include more than 27 million urine tests and more than 840 thousand hair tests performed by Quest Diagnostics between 2005 and the first half of 2009. Testing of urine specimens can detect a single instance of drug use in the prior one to three days, while hair testing can detect a pattern of repetitive use over a period of up to 90 days.

Click here to view the full release.

Federally Mandated Testing Changes

by Aaron Atkinson on November 20, 2009

The department of Health and Human Services Administration (HHS) issued a rule that will affect Federal workforce drug testing programs. Beginning in May 2010, MDMA (Ecstasy) and 6-Acetylmorphine (Heroin-specific metabolite) will become required screens in regulated panels. Additionally, the screening and confirmation cutoffs for cocaine and amphetamines will be lowered. The Department of Transportation (DOT) has not yet issued a NPRM adopting these HHS changes, but we anticipate that they will in the next several weeks.

Once these changes go into affect, your Federally mandated drug testing may see an increase in positive tests, primarily, due to the lower cut-offs . This could cause increased laboratory costs and Medical Review Officer (MRO) fees, and more results with increased turnaround times.

While this change will directly apply to your Federally-mandated testing, a number of our clients administer their non-DOT testing by adhering to Federal testing standards. We will not be taking automatic action to change any of your non-DOT panels without your written authorization. Despite the potential negative return on your investment, if you would like for your non-DOT test panels to continue to match the DOT panels and cutoffs, please call our National Customer Support Center at 800-877-7484.

As the industry leader and your drug testing partner we will continue to monitor and inform you as more specifics are made available. Quest Diagnostics will be prepared to implement all required testing changes to keep you in compliance with both your company policy and Federal drug testing regulations. Look for future Results articles on the topic over the coming months and do not hesitate to contact us with any questions that you might have in the meantime.

USA Today Runs DTI Article

November 20, 2009 Industry News

On November 20, 2009, Quest Diagnostics published our first Drug Testing Index TM with hair testing data. USA Today ran an article about our release: Newer workplace drug tests using hair samples reveal 10 times as many job applicants and employees taking cocaine and methamphetamine than had been found in urine tests. Quest Diagnostics on [...]

Read the full article →

Medical Marijuana

November 12, 2009 Drugs & Testing

The following article was published by the U.S. Department of Transportation Office of Drug & Alcohol Policy & Compliance (ODAPC). “Recently, the Department of Justice (DOJ) issued guidelines for Federal prosecutors in states that have enacted laws authorizing the use of “medical marijuana.” Click here to view the guidelines. “We have had several inquiries about [...]

Read the full article →

Steroids – An FDA Advisory

November 12, 2009 Drugs & Testing

In addition to drug testing and wellness screening services for employers, Quest Diagnostics also offers a variety of panels that test for steroids and other performance-enhancing substances. With this in mind, a recent notice from the FDA caught our attention and we wanted to pass along some important information. While it is common to think [...]

Read the full article →